Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia

Taylor‐Rowan, Martin; Kraia, Olga; Kolliopoulou, Christina; Noel-Storr, Anna; AlHarthi, Ahmed S; Cross, Amanda J.; Stewart, Carrie; Myint, Phyo Kyaw; McCleery, Jenny; Quinn, Terry

doi:10.1002/14651858.cd015196.pub2

Cited by 6 publications

(1 citation statement)

References 89 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A trial is currently underway to compare the effectiveness of different types of reduction interventions (e.g., pharmacist-led versus GP-led; educational versus audit and feedback) in reducing overall anticholinergic burden; to establish optimal duration of anticholinergic reduction interventions; sustainability and lessons learned for upscaling; and to compare results according to differing anticholinergic scales used in medication reduction intervention trials [ 100 ].…”

Section: How Can We Lessen the Impact Of Ab On Bpsd?mentioning

confidence: 99%

Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases

Mahmoudi

Novella

Laurent-Badr

et al. 2023

IJMS

View full text Add to dashboard Cite

Cholinergic antagonists interfere with synaptic transmission in the central nervous system and are involved in pathological processes in patients with neurocognitive disorders (NCD), such as behavioral and psychological symptoms of dementia (BPSD). In this commentary, we will briefly review the current knowledge on the impact of cholinergic burden on BPSD in persons with NCD, including the main pathophysiological mechanisms. Given the lack of clear consensus regarding symptomatic management of BPSD, special attention must be paid to this preventable, iatrogenic condition in patients with NCD, and de-prescription of cholinergic antagonists should be considered in patients with BPSD.

show abstract

Section: How Can We Lessen the Impact Of Ab On Bpsd?mentioning

confidence: 99%

Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases

Mahmoudi

Novella

Laurent-Badr

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

Taylor‐Rowan

AlHarthi

Noel-Storr

et al. 2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

Taylor-Rowan,

Alharthi,

Noel-Storr

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia

Abstract: Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia (Protocol)

Cited by 6 publications

References 89 publications

Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases

Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases

Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment

Contact Info

Product

Resources

About